Lexicon Pharmaceuticals
LXRX
105 hedge funds and large institutions have $280M invested in Lexicon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 7 closing their positions.
329% more call options, than puts
Call options by funds: $296K | Put options by funds: $69K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
7% more funds holding
Funds holding: 98 → 105 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.25% less ownership
Funds ownership: 81.08% → 77.83% (-3.3%)
22% less capital invested
Capital invested by funds: $357M → $280M (-$77.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$576K |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$286K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$250K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$249K |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.83M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$539K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$224K |
| 4 |
Natixis Advisors
Boston,
Massachusetts
|
-$212K |
| 5 |
PA
Pinnacle Associates
New York
|
-$209K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CASC
101
Coppell Advisory Solutions Corp
Coppell,
Texas
| $216 | +$240 | +113 | New |
|
102
CIBC Private Wealth Group
Atlanta,
Georgia
| $57 | – | – | – |
|
|
103
Natixis Advisors
Boston,
Massachusetts
| – | -$212K | -88,411 | Closed |
|
104
Norges Bank
Oslo,
Norway
| – | -$199K | -82,900 | Closed |
|
|
GCP
105
GSA Capital Partners
London,
United Kingdom
| – | -$170K | -71,004 | Closed |
|
|
HF
106
HRT Financial
New York
| – | -$109K | -45,569 | Closed |
|
|
VF
107
Virtu Financial
New York
| – | -$32K | -13,458 | Closed |
|
108
Wells Fargo
San Francisco,
California
| – | -$2K | -761 | Closed |
|
|
SFCL
109
Strengthening Families & Communities LLC
Boston,
Massachusetts
| – | +$2 | +1 | New |
|
110
Nisa Investment Advisors
St. Louis,
Missouri
| – | +$143 | +67 | New |
|
LXRX Hedge Fund Activity: Q4 2022 in Review
105 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2022, worth a combined $280M — down 22% from $357M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LXRX positions and 7 closed out — a net gain of 7 holders — while 38 added to existing stakes and 32 trimmed.
The largest buyer was Millennium Management, adding an estimated $576K. The largest seller was Point72 Asset Management, cutting an estimated $4.83M.
- 105 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2022, up from 98 in Q3 2022.
- Funds reported $280M of Lexicon Pharmaceuticals stock for Q4 2022, down 22% quarter-over-quarter.
- 14 funds opened new Lexicon Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +7 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $576K added.
- The largest Lexicon Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $4.83M sold.
Based on aggregated 13F filings for Q4 2022.